Xu Suqing, Xie Xi, Tang Mengshi, Chen Jinwei, Tian Jing, Du Jinfeng, Mao Ni, Liu Yiming, Li Shu, Song Meiyan, Gao Jiesheng, Ling Guanghui, Li Fen
Department of Rheumatology, Second Xiangya Hospital, Central South University, Changsha 410011, China.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2017 Oct 28;42(10):1174-1177. doi: 10.11817/j.issn.1672-7347.2017.10.008.
To evaluate therapeutic effects and adverse reactions of tocilizumab on patients with severe active rheumatoid arthritis (RA). Methods: Twelve patients with severe refractory RA were treated with tocilizumab. The clinical and laboratory indices and the side effects were recorded after treatment. Results: The clinical and laboratory indices and the disease activity score 28 (DAS28) were observed in all patients, which were significantly improved after TCZ therapy (P<0.05), and no obvious adverse reactions were found. Conclusion: Tocilizumab can effectively relieve the symptoms and improve the conditions of severe active RA.
评估托珠单抗对重度活动性类风湿关节炎（RA）患者的治疗效果及不良反应。方法：12例重度难治性RA患者接受托珠单抗治疗。治疗后记录临床和实验室指标及副作用。结果：观察所有患者的临床和实验室指标及疾病活动度评分28（DAS28），托珠单抗治疗后均显著改善（P<0.05），且未发现明显不良反应。结论：托珠单抗可有效缓解重度活动性RA患者的症状并改善病情。
